The second highest year on record, 2023 saw huge PE interest in life sciences and biopharma sectors.
Here are three more key notes that ASC leaders need to know:
- The first half of 2022 saw a continuation of 2021’s record-breaking healthcare private equity deal pace, but transactions slowed in the second half of the year.
- Value-based care and primary care continued to draw investment from private equity groups.
- More than 40 exits valued above $500 million were closed in 2022.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.